Evidence map›Paper›PMID 32040731›Full record

SynthesisEuropean radiology2020

The prognostic value of late gadolinium enhancement in myocarditis and clinically suspected myocarditis: systematic review and meta-analysis.

Fuyao Yang, Jie Wang, Weihao Li, Yuanwei Xu, Ke Wan, Rui Zeng, Yucheng Chen

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in European radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Cardiac MRI at Low Field Strengths.Journal of magnetic resonance imaging : JMRI · 2024
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Role of Endomyocardial Biopsy in Diagnostics of Myocarditis.Diagnostics (Basel, Switzerland) · 2022
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Fuyao YangDepartment of Cardiology, West China Hospital, Sichuan University, Guoxue Xiang No. 37, Chengdu, 610041, Sichuan, China.
Jie WangDepartment of Cardiology, West China Hospital, Sichuan University, Guoxue Xiang No. 37, Chengdu, 610041, Sichuan, China.
Weihao LiDepartment of Cardiology, West China Hospital, Sichuan University, Guoxue Xiang No. 37, Chengdu, 610041, Sichuan, China.
Yuanwei XuDepartment of Cardiology, West China Hospital, Sichuan University, Guoxue Xiang No. 37, Chengdu, 610041, Sichuan, China.
Ke WanDepartment of Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, People's Republic of China.
Rui ZengDepartment of Cardiology, West China Hospital, Sichuan University, Guoxue Xiang No. 37, Chengdu, 610041, Sichuan, China. zengrui_0524@126.com.
Yucheng ChenDepartment of Cardiology, West China Hospital, Sichuan University, Guoxue Xiang No. 37, Chengdu, 610041, Sichuan, China. chenyucheng2003@126.com.ORCID http://orcid.org/0000-0001-8480-4054
Sichuan University · CN

Funding

1·3·5 project for disciplines of excellence, West China Hospital, Sichuan University ZYJC18013National Natural Science Foundation of China 81571638
6 · The paper itself

Abstract

objectiveTo evaluate the prognostic value of late gadolinium enhancement (LGE) in myocarditis and clinically suspected myocarditis.

methodsThe study was registered in PROSPERO (CRD42019144976). A systematic search of PubMed, Ovid Medline, Embase, Web of Science and the Cochrane Central Register of Controlled Trials was completed. Major adverse cardiac event (MACE) was defined as the combination of all-cause mortality or cardiovascular death, resuscitated cardiac arrest, heart transplantation, appropriate implantable cardioverter-defibrillator shock, rehospitalisation following a cardiac event and recurrent acute myocarditis. Combined outcome was defined as the combination of all adverse events. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate the prognostic value of LGE.

resultsEight articles including 1319 patients (mean age, 38.8 ± 12.9 years) were included in the meta-analysis. The study showed that positive LGE was strongly associated with an increased risk of combined outcome (pooled OR, 5.85; 95% CI, 2.88 to 11.86; p < 0.001) and of MACE (pooled OR, 4.57; 95% CI, 2.18 to 9.59; p < 0.001). Additionally, in a subgroup analysis with mean ejection fraction (EF) point of 50%, the pooled ORs for the combined outcome were 6.46 for left ventricular EF (LVEF) > 50% and 7.90 for LVEF ≤ 50%, and the pooled ORs for MACE were 9.03 and 3.45, respectively. After 3 years of follow-up, the worse outcomes occurred mainly in patients with positive LGE.

conclusionPositive LGE is a powerful prognosticator of adverse outcome in myocarditis and clinically suspected myocarditis, irrespective of LVEF. KEY POINTS: • Forty-four percent to 100% of myocarditis patients have positive late gadolinium enhancement. • Positive LGE was a powerful prognosticator of adverse outcome in myocarditis and clinically suspected myocarditis, irrespective of LVEF. • LGE-CMR is important tool for risk stratification in myocarditis and clinically suspected myocarditis.

Indexed as

MortalityCardiovascular DiseasesContrast MediaElectric CountershockGadoliniumHeart ArrestHeart TransplantationHumansMagnetic Resonance ImagingMyocarditisOdds RatioPatient ReadmissionPrognosisRecurrenceRisk FactorsStroke VolumeContrast MediaGadoliniumFibrosisMagnetic resonance imagingMeta-analysisMyocarditisPrognosis

Identifiers

PMID32040731
OpenAlexW3006033223

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.